Pharmacokinetics and Pharmacodynamics of antenatal corticosteroids when given to woman at risk of late preterm birth - NI

World Health Organization0 sites0 target enrollmentTBD

ConditionsHealth Condition 1: P220- Respiratory distress syndrome of newborn

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Health Condition 1: P220- Respiratory distress syndrome of newborn
Sponsor: World Health Organization
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

last year

Study Type

Interventional

Investigators

Sponsor

World Health Organization

Eligibility Criteria

Inclusion Criteria

•Consecutive women enrolled into the ACTION III trial at the two Indian sites, KLE Academy of Higher Education and Research and VMMC \& Safdarjung hospital will be approached over a period of 4 months.

Exclusion Criteria

•ACTION III participants who are diabetic, severely anaemic or with features of HELLP syndrome will be excluded

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting

Phase 2

Maternal pharmacokinetics and pharmacodynamics of nicardipine (iv) during treatment of severe hypertension in pregnancy.preeclampsia1002690810057166

NL-OMON36863Erasmus MC, Universitair Medisch Centrum Rotterdam40

Active, Not Recruiting

N/A

What is the effect of nicardipine on the pregnant woman with severe hypertension and how is nicardipine excreted?

EUCTR2012-005330-10-NLErasmus University Medical Centre

Active, Not Recruiting

N/A

APPA Neonatal and Paediatric Penicillins StudyThe study is not restricted to any specific condition. The study population will include children (aged under 16 years) admitted to hospital and routinely prescribed one of the study penicillins according to local hospital policy for any indication (including medical or surgical prophylaxis).Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

EUCTR2013-002366-40-GBSt George’s, University of London

Active, Not Recruiting

N/A

Pharmacokinetics, pharmacodynamics and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patientsProstate cancerMedDRA version: 8.1Level: LLTClassification code 10007113Term: Cancer of prostate

EUCTR2006-005964-24-GBItalfarmaco S.p.A.20

Completed

Phase 3

The influence of twin pregnancy on the kinetic disposition and crossing of the placental barrier of betamethasone

RBR-2v2mwkzFaculdade de Medicina de Ribeirão Preto